Literature DB >> 22592288

IVIG treatment in post-polio patients: evaluation of responders.

Gunilla Ostlund1, Lisbet Broman, Lars Werhagen, Kristian Borg.   

Abstract

The aim of this work is to evaluate the outcome of IVIG treatment in patients with post-polio syndrome (PPS) and to identify responders. The study included 113 PPS patients who had received one IVIG treatment in an open trial, prospective follow-up study. Clinical examination was performed and clinical data were retrieved from medical records. The short form 36 (SF-36), physical activity scale for the elderly (PASE), and the visual analogue scale (VAS) were used as measurements of quality of life, physical activity, and the intensity of pain. Data before treatment and at 6-month follow-up were collected. Analysis was performed in subgroups based on demographic and medical parameters. A statistically significant increase of the SF-36 sub domains bodily pain, vitality, social function, role emotional, and the mental compound score (MCS) was found at the 6-month follow-up. A significant decrease of pain was found in patients who reported pain intensity over VAS of 20 mm, in patients younger than 65 years of age and in patients who had paresis in the lower extremities. A trend was found in patients with PPS as the only diagnosis. IVIG leads to increase of quality of life at 6-month follow-up for SF-36 regarding sub domains of bodily pain, vitality, social function, role emotional, as well as for pain. Age below 65 years, paresis in the lower extremities, and lack of concomitant disorders may be the main indicators for a future identification of responders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592288     DOI: 10.1007/s00415-012-6538-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  20 in total

1.  Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial.

Authors:  Henrik Gonzalez; Katharina Stibrant Sunnerhagen; Inger Sjöberg; Georgios Kaponides; Tomas Olsson; Kristian Borg
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

Review 2.  A comprehensive review of the placebo effect: recent advances and current thought.

Authors:  Donald D Price; Damien G Finniss; Fabrizio Benedetti
Journal:  Annu Rev Psychol       Date:  2008       Impact factor: 24.137

3.  The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population.

Authors:  M Sullivan; J Karlsson
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

Review 4.  Current status of poliovirus infections.

Authors:  J L Melnick
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

Review 5.  Post-poliomyelitis syndrome.

Authors:  Daria A Trojan; Neil R Cashman
Journal:  Muscle Nerve       Date:  2005-01       Impact factor: 3.217

6.  The physical activity scale for the elderly (PASE): evidence for validity.

Authors:  R A Washburn; E McAuley; J Katula; S L Mihalko; R A Boileau
Journal:  J Clin Epidemiol       Date:  1999-07       Impact factor: 6.437

7.  Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production.

Authors:  Henrik Gonzalez; Mohsen Khademi; Magnus Andersson; Fredrik Piehl; Erik Wallström; Kristian Borg; Tomas Olsson
Journal:  J Neuroimmunol       Date:  2004-05       Impact factor: 3.478

8.  Elevated serum inflammatory markers in post-poliomyelitis syndrome.

Authors:  Christopher B Fordyce; Donald Gagne; Farzaneh Jalili; Sudabeh Alatab; Douglas L Arnold; Deborah Da Costa; Stefan Sawoszczuk; Caroline Bodner; Stan Shapiro; Jean-Paul Collet; Ann Robinson; Jean-Pierre Le Cruguel; Yves Lapierre; Amit Bar-Or; Daria A Trojan
Journal:  J Neurol Sci       Date:  2008-05-12       Impact factor: 3.181

9.  Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation.

Authors:  Henrik Gonzalez; Jan Ottervald; Kerstin C Nilsson; Niclas Sjögren; Tasso Miliotis; Helena Von Bahr; Mohsen Khademi; Bodil Eriksson; Sven Kjellström; Akos Vegvari; Robert Harris; György Marko-Varga; Kristian Borg; Johan Nilsson; Thomas Laurell; Tomas Olsson; Bo Franzén
Journal:  J Proteomics       Date:  2008-12-03       Impact factor: 4.044

Review 10.  Management of postpolio syndrome.

Authors:  Henrik Gonzalez; Tomas Olsson; Kristian Borg
Journal:  Lancet Neurol       Date:  2010-06       Impact factor: 44.182

View more
  2 in total

1.  Survey of young patients with polio and a foreign background at a Swedish post-polio outpatient clinic.

Authors:  Lars Werhagen; Kristian Borg
Journal:  Neurol Sci       Date:  2016-06-14       Impact factor: 3.307

Review 2.  Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis.

Authors:  Yao-Hsien Huang; Hung-Chou Chen; Kuang-Wei Huang; Po-Chih Chen; Chaur-Jong Hu; Chin-Piao Tsai; Ka-Wai Tam; Yi-Chun Kuan
Journal:  BMC Neurol       Date:  2015-03-22       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.